Click here to read the articles and download the PDF

Pharmaceutical Commerce - December 2024

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

Did Industry Fumble the DSCSA Deadline?

A crash course on the bubble itself, including therapeutic areas most affected.

Going Inside the Gross-to-Net Bubble and Its Nuances

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

Why AI Advances in CGT Require Getting Data Right

Articles

One lot of the company’s branded dextroamphetamine sulfate tablets is being removed from shelves nationwide due to a pharmacy receiving carbinoxamine maleate instead. 

Azurity Pharmaceuticals Recalls Zenzedi

A non-randomized control trial investigates whether older adults with multiple chronic conditions can benefit by receiving more specialized services.

Does Patient Priorities Care Result in Better Outcomes for Patients?

GLP-1 agonists may be an effective therapy to avoid severe liver disease in those with concurrent type 2 diabetes.

GLP-1 Agonists Could Be Key in Reducing Severe Liver Disease for Type 2 Diabetes Patients

Michael Christel is Group Managing Editor of Pharmaceutical Commerce, Pharmaceutical Executive, and Applied Clinical Trials. He can be reached at mchristel@mjhlifesciences.com.

A deep dive into the complex playing field for M&A and partnering pursuits in today’s increasingly make-or-break landscape for biopharma innovation. 

The Twists and Turns in Biopharma Dealmaking: 2024 Trends

As providers and healthcare professionals recognize the potential of long-acting injectables to fight the opioid epidemic, many are actively transitioning from oral options to injectables.

Breaking the Chains of Opioid Addiction: The Promise of Long-Acting Injectables 

The Identification of Medicinal Product framework seeks to establish a common language for identifying, documenting, and exchanging information about medicinal products.

Challenges and Benefits of Implementing IDMP in the Pharmaceutical Industry

Concerns regarding hypoglycemia potentially linked to a counterfeit version of Ozempic come at a time in which reports have grown regarding the improper use of GLP-1 receptor agonists for the purpose of cosmetic weight loss.

Adverse Event Reports Linked to Counterfeit Ozempic on the Rise

Dupixent is now the first and only treatment option for eosinophilic esophagitis in patients aged 1 and older, weighing at least 15 kg.

Dupixent Approved for Expanded Indication in Children Under 12 Years With Eosinophilic Esophagitis 

As technology continues to advance, investigators explore the legal protocol for how to handle AI-responsible injuries.

Examining the Liability Risk Surrounding Artificial Intelligence Tools in the Healthcare Environment 

Zynrelef was initially approved by the FDA for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours following bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.

Featured Content

Pharmaceutical Commerce - December 2024

Did Industry Fumble the DSCSA Deadline?

Going Inside the Gross-to-Net Bubble and Its Nuances

Why AI Advances in CGT Require Getting Data Right